Disease Intelligence Center · Pandemic II
Obesity & Metabolic Dysfunction
Obesity is modeled as a disorder of energy signaling rather than a BMI value: endocrine-active exposures, mitochondrial and redox function, insulin, leptin, thyroid and sex-hormone signaling, adipose inflammation, microbiome relationships and nutrient adequacy are each evaluated separately.
Domain weighting
Organizational emphasisiWeightings describe where this framework directs attention for this condition. They are not a measure of how much any factor caused an individual case.
Root-cause chain
Each link carries its own evidence grade- Endocrine-active chemical exposure→Receptor and signaling interactionTD
In-vitro and animal work shows nuclear-receptor binding and altered transcription of adipogenic genes. Human exposure data come from population biomonitoring; detection alone does not establish an effect.
Relationship: Mechanistic plausibility
- Altered insulin and leptin signaling→Adipocyte dysfunctionBB
Cohort data link hyperinsulinemia and leptin resistance to adipocyte hypertrophy and impaired lipolysis; interventional data are narrower.
Relationship: Observational association
- Visceral adipose inflammation→Insulin resistanceIA
Macrophage infiltration and cytokine release impair insulin receptor substrate signaling; consistently reproduced across human and animal evidence.
Relationship: Established causal
- Ultra-processed dietary pattern→Excess energy intake and weight gainNA
Controlled feeding trials show higher ad-libitum energy intake and weight gain on ultra-processed diets at matched macronutrients.
Relationship: Randomized evidence
iDetection of an exposure does not establish that it caused a disease. This platform separates exposure, association, plausible mechanism, clinical evidence and demonstrated causation.
Fifth Estate considerations
Microbial ecologyBacteriome shifts and SCFA production are evaluated as a dysbiosis hypothesis, not an infection. Antimicrobials are not indicated on the basis of a microbiome pattern alone.
Go deeper
TOBIN Intelligence LibraryThe full evidence review for Obesity & Metabolic Dysfunction: each mechanism by domain, what is established versus uncertain, related pandemics, relevant labs and how they move your scores.
Open the Obesity & Metabolic Dysfunction evidence reviewProtocol Fusion Engine
Six lanes · evidence grade and regulatory status on every entryConventional
Reduces weight and cardiometabolic events in guideline-eligible patients.
Caution: Contraindicated with personal/family medullary thyroid carcinoma or MEN2; monitor GI tolerance, gallbladder and pancreatitis signals.
Functional
Short and irregular sleep worsens insulin sensitivity and appetite regulation.
Caution: Screen for obstructive sleep apnea before attributing fatigue to habits.
Integrative
Improves insulin sensitivity and preserves lean mass during weight loss.
Caution: Cardiac clearance where symptoms or risk factors are present.
Orthomolecular
Corrects a measured deficiency; not a weight-loss intervention on its own.
Caution: Dose to measured 25-OH vitamin D; caution in hypercalcemia, sarcoidosis and thiazide use.
Traditional
Consistent cardiometabolic benefit across trials and cohorts.
Caution: Adapt to allergy, renal and cultural context.
Energy / Physical
Energy medicine on Tayapulse →Limited preliminary evidence for muscle recovery; no evidence for fat loss.
Caution: Must not be presented as a treatment for obesity or metabolic disease.
iLanes are presented side by side so the difference in evidence strength is visible. Nothing here is a prescription, and interactions must be reviewed with your clinician and pharmacist.
iEnergy and physical modalities in this lane are explored further with Tayapulse. Evidence grade and regulatory status still apply: these are adjuncts used only where indicated, never cures or replacements for guideline care.
Diagnostics to consider
- · Body composition and waist circumference
- · Fasting glucose, insulin, HbA1c, HOMA-IR
- · Lipid panel with ApoB and Lp(a)
- · Liver enzymes and hepatic imaging where indicated
- · Thyroid studies and sex hormones when clinically justified
Monitoring
- · Weight and waist trend every 30 days
- · HbA1c and lipids at 90 and 180 days
- · Medication review at each visit
- · TOBIN score change over time
Prevention emphasis
- · Reduce ultra-processed food share
- · Protein and fiber adequacy at each meal
- · Sleep regularity and 7–9 hours
- · Reduce avoidable endocrine-active exposures
- · Resistance training twice weekly